Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Eisai prepares potent antitumor agents

April 11, 1997

TX-1877: new hypoxic cell radiation enhancer

April 11, 1997

MDR-reversing agents described by Nikken Chemicals

April 11, 1997

UCSF receives NIH funding for research into anticancer protease inhibitors

April 11, 1997

Farnesyltransferase inhibitors from Zeneca

April 10, 1997

Pharma Mar describes antitumor compounds from marine sponge

April 10, 1997

IntraBiotics initiates phase I trials of IB-367 for oral mucositis

April 10, 1997

Sugen receives patent coverage for GRB2 cancer target

April 9, 1997

NIH licenses PTC gene for cancer diagnosis and therapy

April 9, 1997

Nigella sativa plant extract exerts antiangiogenic activity

April 8, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...